Endothelial dysfunction as a determinant of trastuzumabmediated cardiotoxicity in patients with breast cancer

Anticancer Research

Volumn 34, Issue 3, 2014, Pages 1147-1151

  Sandoo, Aamer ^a   Kitas, George D ^a   Carmichael, Amtul R ^a  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Cardiotoxicity; Endothelium; Herceptin; Review; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; HEART MUSCLE; HUMAN; OUTCOME ASSESSMENT; PROTEIN FUNCTION; REVIEW; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; ENDOTHELIUM; FEMALE; HEART DISEASE; PATHOLOGY; PROGNOSIS; VASCULAR ENDOTHELIUM;

BREAST CANCER; CARDIOTOXICITY; ENDOTHELIUM; HERCEPTIN; REVIEW; TRASTUZUMAB;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ENDOTHELIUM, VASCULAR; FEMALE; HEART DISEASES; HUMANS; PROGNOSIS;

EID: 84899684721     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS and Gelber RD: Trastuzumab after adjuvant chemotherapy in HER2- positive breast cancer. N Engl J Med 353: 1659-1672, 2005.
4. Wadhwa D, Fallah-Rad N, Grenier D, Krahn M, Fang T, Ahmadie R, Walker JR, Lister D, Arora RC, Barac I, Morris A and Jassal DS: Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: A retrospective study. Breast Cancer Res Treat 117: 357-364, 2009.
5. Gutierrez C and Schiff R: HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135: 55-62, 2011.
6. Zeglinski M, Ludke A, Jassal DS, and Singal PK: Trastuzumabinduced cardiac dysfunction: A 'dual-hit'. Exp Clin Cardiol 16: 70-74, 2011.
7. Di Cosimo S: Heart to heart with trastuzumab: A review on cardiac toxicity. Target Oncol 6: 189-195, 2011.
8. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, and Kitchen P: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11: 1936-1942, 1993.
9. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S and Bast RC: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091, 1990.
10. Yu D and Hung MC: Overexpression of ERBB2 in cancer and ERBB2-targeting strategies. Oncogene 19: 6115-6121, 2000.
11. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW and Leahy DJ: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760, 2003.
12. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N, Chien KR, Birchmeier C and Garratt AN: Conditional mutation of the ERBB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 99: 8880-8885, 2002.
13. Jiang Z and Zhou M: Neuregulin signaling and heart failure. Curr Heart Fail Rep 7: 42-47, 2010.
14. Pentassuglia L and Sawyer DB: The role of neuregulin-1beta/ErbB signaling in the heart. Exp Cell Res 315: 627-637, 2009.
15. Sandoo A, Veldhuijzen van Zanten JJCS, Metsios GS, Carroll D and Kitas GD: The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J 4: 302-312, 2010.
16. Kuramochi Y, Guo X and Sawyer DB: Neuregulin activates ErbB2-dependent Src/Fak signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 41: 228-35, 2006.
17. Lemmens K, Doggen K and De Keulenaer GW: Role of neuregulin-1/ERBB signaling in cardiovascular physiology and disease: Implications for therapy of heart failure. Circulation 116: 954-960, 2007.
18. Lemmens K, Segers VF, Demolder M and De Keulenaer GW: Role of neuregulin-1/ErbB2 signaling in endotheliumcardiomyocyte cross-talk. J Biol Chem 281: 19469-19477, 2006.
19. Nakagami H, Takemoto M and Liao JK: NADPH oxidasederived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 35: 851-859, 2003.
20. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C and Cipolla CM: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114: 2474-2481, 2006.
21. Cai H and Harrison DG: Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 87: 840-844, 2000.
22. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ and Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002.
23. National Institute for Health and Clinical Excellence: Trastuzumab for the adjuvant treatment of early stage HER2- positive breast cancer. NICE technology appraisal guidance 2007. http://www.nice.org.uk/nicemedia/live/11586/33458/33458.pdf.
24. Levick JR: An Introduction to Cardiovascular Physiology. Oxford University Press, London, 2003.
25. Fischer D, Rossa S, Landmesser U, Spiekermann S, Engberding N, Hornig B and Drexler H: Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 26: 65-69, 2005.
26. Lerman A and Zeiher AM: Endothelial function: Cardiac events. Circulation 111: 363-368, 2005.
27. Furchgott RF and Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376, 1980.
28. Vallance P, Collier J and Moncada S: Effects of endotheliumderived nitric oxide on peripheral arteriolar tone in man. Lancet 2: 997-1000, 1989.
29. Palmer RM, Ashton DS and Moncada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333: 664-666, 1988.
30. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG and Marsden PA: Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 17: 2479-2488, 1997.
31. Channon KM: Tetrahydrobiopterin: Regulator of endothelial nitric oxide synthase in vascular disease. Trends Cardiovasc Med 14: 323-327, 2004.
32. Hornig B, Arakawa N, Haussmann D and Drexler H: Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 98: 2842-2848, 1998.
33. Giannattasio C, Achilli F, Grappiolo A, Failla M, Meles E, Gentile G, Calchera I, Capra A, Baglivo J, Vincenzi A, Sala L and Mancia G: Radial artery flow-mediated dilatation in heart failure patients: Effects of pharmacological and nonpharmacological treatment. Hypertension 38: 1451-1455, 2001.
34. Buus NH, Bottcher M, Hermansen F, Sander M, Nielsen TT and Mulvany MJ: Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation 104: 2305-2310, 2001.
35. de Berrazueta JR, Guerra-Ruiz A, Garcia-Unzueta MT, Martin Toca G, Sainz Laso R, de Adana MS, Casanova Martin MA, Cobo M and Llorca J: Endothelial dysfunction, measured by reactive hyperaemia using strain-gauge plethysmography, is an independent predictor of adverse outcome in heart failure. Eur J Heart Failure 12: 477-483, 2010.
36. Hornig B, Maier V and Drexler H: Physical training improves endothelial function in patients with chronic heart failure. Circulation 93: 210-214, 1996.
37. Hornig B, Arakawa N, Kohler C and Drexler H: Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 97: 363-368, 1998.